IP Library Granted Patent US 6,979,468
Granted Patent B1
US 6,979,468 · App. 10/313,165 · Granted Dec 27, 2005

Oral composition and method for the treatment of inflammatory cutaneous disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,979,468
App. No.
10/313,165
Granted
Dec 27, 2005
Kind
B1
Abstract

A method and composition for the treatment of acne vulgaris, acne rosacea, and other inflammatory skin conditions comprises the oral administration of a composition comprising a dose of nicotinamide delivered at levels substantially in excess of normal dietary levels, the nicotinamide being delivered in combination with zinc. The composition may also include quantities of copper and folic acid. In a most preferred embodiment, the nicotinamide and copper each are present in immediate release formats, while the zinc is present in a sustained release format.

Claims (16)

1. An oral pharmaceutical preparation in dosage unit form adapted for administration for the treatment of inflammatory skin disorders, comprising, per dosage unit, at least 250 mg of nicotinamide in an immediate release form, and an amount of zinc in a sustained release form, said amount of zinc being sufficient to provide an enhanced anti-inflammatory effect, in a vehicle pharmaceutically acceptable for oral administration.

2. The oral pharmaceutical preparation of claim 1 wherein said zinc is present as zinc oxide, zinc sulfate, zinc gluconate, zinc complexes or zinc chelates.

3. The oral pharmaceutical preparation of claim 2 wherein said zinc is present as zinc oxide in the amount of about at least 15 mg per dosage unit.

4. The oral pharmaceutical preparation of claim 3 wherein said zinc oxide is present in the amount of about at least 20 mg per dosage unit.

5. The oral pharmaceutical preparation of claim 4 wherein said zinc oxide is present in the amount of about at least 25 mg per dosage unit.

6. The oral pharmaceutical preparation of claim 1 further comprising an amount of folic acid.

7. The oral pharmaceutical preparation of claim 6 wherein said folic acid is present in the amount of at least about 500 micrograms per dosage unit.

8. The oral pharmaceutical preparation of claim 1 wherein said nicotinamide is present in the amount of about at least 500 mg per dosage unit.

9. The oral pharmaceutical preparation of claim 1 wherein said nicotinamide is present in the amount of about at least 750 mg per dosage unit.

10. The oral pharmaceutical preparation of claim 1 further comprising an amount of a copper-containing compound.

11. The oral pharmaceutical preparation of claim 10 wherein said copper-containing compound is in an immediate release form.

12. The oral pharmaceutical preparation of claim 10 wherein said copper-containing compound is selected from the group consisting of cupric oxide, cupric sulfate, copper complexes and copper chelates.

13. The oral pharmaceutical preparation of claim 10 wherein said copper-containing compound is present in an amount of about at least 1.0 milligrams per dosage unit.

14. The oral pharmaceutical preparation of claim 13 wherein said copper-containing compound is present in an amount of about at least 1.5 milligrams per dosage unit.

15. The oral pharmaceutical preparation of claim 1 wherein each dosage unit is in the form of a tablet, capsule or softgel.

16. A method for the treatment of inflammatory skin conditions, the method comprising the step of orally administering to a person having said inflammatory skin condition the oral pharmaceutical preparation of claim 1 .

Assignments (12)
SECURITY INTEREST Recorded Aug 27, 2021
From: AVION PHARMACEUTICALS, LLC; SOVEREIGN PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 057310/0385 →
SECURITY INTEREST Recorded Dec 28, 2018
From: AVION PHARMACEUTICALS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 047870/0431 →
RELEASE OF SECURITY INTEREST Recorded Dec 27, 2018
From: SILVER POINT FINANCE LLC
To: ALORA PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC; ACELLA PHARMACEUTICALS, LLC; AVION PHARMACEUTICALS, LLC; NEUVOSYN LABORATORIES, LLC
Reel/Frame 047861/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2016
From: ACELLA PHARMACEUTICALS, LLC
To: AVION PHARMACEUTICALS, LLC
Reel/Frame 039148/0902 →
RELEASE OF SECURITY INTEREST Recorded May 24, 2016
From: MONROE CAPITAL MANAGEMENT ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: ALORA PHARMACEUTICALS, LLC; ACELLA HOLDINGS, INC.; ACELLA PHARMACEUTICALS, LLC; AVION PHARMACEUTICALS, LLC; NEUVOSYN LABORATORIES, LLC
Reel/Frame 038703/0496 →
SECURITY INTEREST Recorded May 20, 2016
From: ALORA PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC; ACELLA PHARMACEUTICALS, LLC; AVION PHARMACEUTICALS, LLC; NEUVOSYN LABORATORIES, LLC
To: SILVER POINT FINANCE, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 038656/0234 →
SECURITY AGREEMENT Recorded Sep 19, 2013
From: ALORA PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC; ACELLA PHARMACEUTICALS, LLC; AVION PHARMACEUTICALS, LLC; NEUVOSYN LABORATORIES, LLC
To: MONROE CAPITAL MANAGEMENT ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031246/0359 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2013
From: WHITEHORSE FINANCE WAREHOUSE, LLC
To: ACELLA PHARMACEUTICALS, LLC; NEUVOSYN LABORATORIES, LLC; AVION PHARMACEUTICALS, LLC; ALORA PHARMACEUTICALS, LLC
Reel/Frame 031230/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2012
From: BAYSIDE FINANCE, LLC
To: WHITEHORSE FINANCE WAREHOUSE, LLC
Reel/Frame 029114/0739 →
SECURITY AGREEMENT Recorded Dec 30, 2011
From: ACELLA PHARMACEUTICALS, LLC; NEUVOSYN LABORATORIS, LLC; AVION PHARMACEUTICALS, LLC; ALORA PHARMACEUTICALS, LLC
To: BAYSIDE FINANCE, LLC
Reel/Frame 027464/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2011
From: DUSA PHARMACEUTICALS, INC.
To: ACELLA PHARMACEUTICALS, LLC
Reel/Frame 026676/0901 →
MERGER Recorded Mar 21, 2006
From: SIRIUS LABORATORIES, INC.
To: DUSA PHARMACEUTICALS, INC.
Reel/Frame 017336/0786 →